StreetInsider.com News Articles

Stereotaxis (STXS) Reiterated at Market Outperform by Citizens

Wed, 03 Jun 2026 04:45:30 -0400

Citizens analyst Daniel Stauder reiterated a Market Outperform rating and $4.00 price target on Stereotaxis (NYSE: STXS).

The analyst commented, "Stereotaxis continues to create a compelling razor/razor blade ecosystem that should provide sustainable growth ahead, and we continue to view the company as a unique microcap name worth owning due to developing tailwinds for system adoption and improved procedural utilization through 2026 and into 2027. Our $4 price target remains based on an EV/revenue multiple of ~6x-7x applied to our 2027 total sales estimate of $53 mln, reflecting a premium high-growth multiple that we view as reasonable given the company's expected

Form SD Stereotaxis, Inc.

Fri, 29 May 2026 15:48:00 -0400

si-local-file:///var/storage/secattach/20260529/26574738.html

Form SD Stereotaxis, Inc.

Fri, 29 May 2026 15:48:00 -0400

si-local-file:///var/storage/secattach/20260529/26574738.html

Form SCHEDULE 13G/A Stereotaxis, Inc. Filed by: Lagoda Investment Management, L.P.

Fri, 15 May 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260515/26505049.html

Form SCHEDULE 13G/A Stereotaxis, Inc. Filed by: Lagoda Investment Management, L.P.

Fri, 15 May 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260515/26505049.html

Form 8-K Stereotaxis, Inc. For: May 14

Fri, 15 May 2026 15:32:00 -0400

si-local-file:///var/storage/secattach/20260515/26504291.html

Form 8-K Stereotaxis, Inc. For: May 14

Fri, 15 May 2026 15:32:00 -0400

si-local-file:///var/storage/secattach/20260515/26504291.html

Form 10-Q Stereotaxis, Inc. For: Mar 31

Wed, 13 May 2026 15:42:00 -0400

si-local-file:///var/storage/secattach/20260513/26485516.html

Form 10-Q Stereotaxis, Inc. For: Mar 31

Wed, 13 May 2026 15:42:00 -0400

si-local-file:///var/storage/secattach/20260513/26485516.html

Stereotaxis (STXS) PT Lowered to $3.50 at Piper Sandler

Wed, 13 May 2026 07:22:49 -0400

Piper Sandler analyst Adam Maeder lowered the price target on Stereotaxis (NYSE: STXS) to $3.50 (from $4.00) while maintaining a Overweight rating.

Form 8-K Stereotaxis, Inc. For: May 12

Tue, 12 May 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260512/26477918.html

Form 8-K Stereotaxis, Inc. For: May 12

Tue, 12 May 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260512/26477918.html

Stereotaxis (STXS) Misses Q1 EPS by 1c

Tue, 12 May 2026 16:08:05 -0400

Stereotaxis (NYSE: STXS) reported Q1 EPS of ($0.06), $0.01 worse than the analyst estimate of ($0.05). Revenue for the quarter came in at $6.29 million versus the consensus estimate of $8.72 million.

For earnings history and earnings-related data on Stereotaxis (STXS) click here.

Stereotaxis Reports 2026 First Quarter Financial Results & Business Updates

Tue, 12 May 2026 16:06:00 -0400

Proprietary robotically-navigated MAGiC catheter received U.S. FDA approval in January and is now being utilized at multiple sites across the United States as well as Europe
Synchrony digital operating room system received U.S. FDA clearance in April and initial orders and shipments are ongoing
Definitive agreement to acquire Robocath creates a leading robotic platform, combining complementary technologies to deliver next-generation fully-integrated robotic solutions for the full spectrum of endovascular procedures

ST. LOUIS, May 12, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular

Stereotaxis Reports 2026 First Quarter Financial Results & Business Updates

Tue, 12 May 2026 16:06:00 -0400

Proprietary robotically-navigated MAGiC catheter received U.S. FDA approval in January and is now being utilized at multiple sites across the United States as well as Europe
Synchrony digital operating room system received U.S. FDA clearance in April and initial orders and shipments are ongoing
Definitive agreement to acquire Robocath creates a leading robotic platform, combining complementary technologies to deliver next-generation fully-integrated robotic solutions for the full spectrum of endovascular procedures

ST. LOUIS, May 12, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular

Stereotaxis Reports 2026 First Quarter Financial Results & Business Updates

Tue, 12 May 2026 16:06:00 -0400

Proprietary robotically-navigated MAGiC catheter received U.S. FDA approval in January and is now being utilized at multiple sites across the United States as well as Europe
Synchrony digital operating room system received U.S. FDA clearance in April and initial orders and shipments are ongoing
Definitive agreement to acquire Robocath creates a leading robotic platform, combining complementary technologies to deliver next-generation fully-integrated robotic solutions for the full spectrum of endovascular procedures

ST. LOUIS, May 12, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular

Stereotaxis Reports 2026 First Quarter Financial Results & Business Updates

Tue, 12 May 2026 16:06:00 -0400

Proprietary robotically-navigated MAGiC catheter received U.S. FDA approval in January and is now being utilized at multiple sites across the United States as well as Europe
Synchrony digital operating room system received U.S. FDA clearance in April and initial orders and shipments are ongoing
Definitive agreement to acquire Robocath creates a leading robotic platform, combining complementary technologies to deliver next-generation fully-integrated robotic solutions for the full spectrum of endovascular procedures

ST. LOUIS, May 12, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular

Stereotaxis Announces First MAGiC Procedures in the United States